Bio Meat Foodtech Follow-up: How Expensive Is the Capital the Partnership Keeps Buying
Bio Meat Foodtech raised too little money in 2025 at too high a capital price. The headline placement price was 40 agorot, but even before the ratchet it was already diluted to roughly 37 agorot per unit, while future units, a derivative liability, warrant relief and deferred management fees were layered around the cash.
The main article already established that the cash balance is the bottleneck in Bio Meat Foodtech. This follow-up isolates the narrower question: how expensive the capital was that the partnership managed to buy for itself in 2025 and the months immediately after. The issue is not only how much cash came in, but how many layers of dilution, investor protection and payment deferral were built around that cash.
The right lens here is all-in cash flexibility, meaning how much real cash was left after the actual cash uses and after the financing terms attached to the money. Through that lens the picture is fairly blunt: year-end cash was only NIS 432 thousand, even after positive financing cash flow of NIS 1.588 million. At the same time, the partnership says explicitly that the cash balance is not enough to support operations for the foreseeable future, that positive cash flow depends on continued fundraising, and that there are material doubts about its ability to continue as a going concern.
- The headline price was not the economic price. The placement was signed at 40 agorot per unit, but once the fixed 8% extra units after 12 months are included, the package already drops to roughly 37 agorot per unit.
- The price-protection layer already cost real value. The derivative meant to protect investors was recognized at NIS 538 thousand on issuance day and remeasured to NIS 566 thousand by December 31, 2025.
- Even after the balance sheet date, cash arrived in drips. Two additional tiny placements followed year-end, first NIS 50 thousand and then NIS 200 thousand, reinforcing that the 2025 package bought more time but did not solve the funding problem.
40 Agorot On Paper, 37 Agorot Even Before The Ratchet
The first number to unpack is the placement price. The official headline is 40 agorot per participation unit. But the same disclosure also includes a fixed extra component: after 12 months, investors receive another 8% in participation units regardless of whether the adjustment mechanism is triggered. So even without activating the ratchet, the economic price of the package is already lower.
The partnership itself states this clearly. The approved framework was 5.95 million participation units plus another 476 thousand units after 12 months, or 6.426 million units in total. Against gross consideration of NIS 2.38 million, that works out to roughly 37 agorot per unit rather than 40. That is already an effective discount of about 7.4% to the headline.
In practice, by the report date the placement had been executed in three stages: 4.075 million units plus 326 thousand rights to units for about NIS 1.63 million, then 125 thousand units plus 10,000 rights for NIS 50 thousand, and later 500 thousand units plus 40 thousand rights for NIS 200 thousand. In other words, the executed structure stayed true to the same economic idea: limited cash up front, with a fixed future dilution layer sitting above it.
What matters is how narrow the market cushion still is. The latest unit price was 40.7 agorot, only about 1.75% above the placement price. That does not mean the ratchet has already been triggered, because the adjustment is tested only after 12 months from the investment date. It does mean that the investor protection embedded in the deal is not sitting far out of the money.
| Layer | What was set | Economic meaning |
|---|---|---|
| Headline price | 40 agorot per unit | The number shown in the deal headline |
| Fixed extra units | 8% after 12 months | This dilution is fixed and does not depend on the ratchet |
| Effective package price | About 37 agorot per unit | Even before the ratchet, capital is already cheaper than the headline implies |
| Adjustment mechanism | Additional issuance if market price is below the investment price | The final economic price can still move lower |
This matters because Bio Meat is not raising abundant growth capital here. It is buying bridge capital. When a company in that position is already paying through fixed extra units and an open-ended price-protection clause on day one, the economic cost of the money is higher than the first number readers see.
Nearly A Third Of The Package Was Assigned To The Derivative
The more unusual part of the deal is not the fixed 8% extra units but the investor-protection mechanism. According to the note, the ratchet component was classified as a derivative liability because it did not meet the Fixed-For-Fixed condition, and it therefore has to be measured at fair value through profit and loss. The derivative was valued at NIS 538 thousand on issuance and at NIS 566 thousand at December 31, 2025.
Those numbers tell a sharp story. Out of NIS 1.681 million of gross proceeds, roughly 32% was assigned to the derivative from day one. By year-end, that liability had already risen to NIS 566 thousand, a number that was actually larger than the cash left on the balance sheet, NIS 432 thousand. In other words, the investor-protection layer by itself was already larger than the cash cushion still sitting in the partnership.
That is still not the whole cost. The cash flow statement also records NIS 45 thousand of issuance costs attributed to the derivative component and charged through profit and loss. So the partnership did not merely split the package between equity, future units and a derivative. It also absorbed an additional accounting cost because of that structure. Total issuance costs came to NIS 175 thousand, or about 10.4% of the gross proceeds.
This is the core of the continuation thesis. Anyone looking only at the 40-agorot headline misses that the package already contained three different price layers: an effective discount through the fixed 8% future units, an open investor-protection clause that keeps living on the balance sheet as a liability, and issuance costs that were high relative to the small amount of money actually raised.
The Cash Bought Time, Not A 2026 Solution
Once the analysis moves from the placement itself to the full cash picture, the reading gets even stricter. Year-end cash stood at just NIS 432 thousand. During the year the partnership used NIS 2.342 million in operating cash flow, invested another NIS 200 thousand in portfolio companies, and ended the year with a NIS 944 thousand decline in cash. So even after the financing package, the cash cushion remained extremely thin.
That ties directly back to the going-concern note. The partnership states that cash and cash equivalents of NIS 432 thousand are not enough to support operations for the foreseeable future, that the annual loss was NIS 6.128 million, and that negative operating cash flow was NIS 2.342 million. The conclusion is explicit: there are material doubts about the partnership's ability to continue as a going concern, and positive cash flow depends on continued fundraising.
This is also where the related-party layer matters. Starting July 1, 2024, the general partner was paid NIS 60 thousand per month instead of NIS 100 thousand, with the remaining NIS 40 thousand plus VAT accrued as a running debt. By the end of 2025 that accumulated debt had reached NIS 802 thousand, versus NIS 234 thousand at the end of 2024. According to the note, repayment can occur only after a net capital raise of more than NIS 1 million, and only if cash after repayment would still be enough for at least 18 months of activity. As of the approval date of the financial statements, that net raise had still not been completed.
At the same time, the related-party note shows a short-term payable of NIS 911 thousand to Bio Meat Ltd., while the non-current liabilities side still carries NIS 4.91 million of initiative-fee liability. So part of the financing flexibility in 2025 was not built from fresh external cash at all. It was also built by pushing internal payments forward.
That is exactly why the change in Warrant Series 2 matters. In November 2025 the exercise deadline was extended to December 7, 2029 from December 7, 2025, and the exercise price was trimmed slightly to 60 agorot from 60.57 agorot. That does not put cash into the company today. It simply keeps another potential dilution layer alive for longer.
After The Balance Sheet Date, Raises Of NIS 50 Thousand And NIS 200 Thousand
If the 2025 package had really solved the funding problem, the post-balance-sheet period should have looked more relaxed. It did not. After year-end the partnership added another placement of 125 thousand units and 10,000 rights for NIS 50 thousand, and then another placement of 500 thousand units and 40,000 rights for NIS 200 thousand.
Together those two raises amounted to only NIS 250 thousand. That is equal to roughly 58% of the year-end cash balance, and only about 16.6% of the net proceeds from the main 2025 placement. In other words, even after the more complex 2025 financing package, the path into 2026 still ran through micro-raises.
That chart matters because it explains why 2025 should be read as time-buying rather than problem-solving. The larger 2025 round brought in NIS 1.506 million net. Then came two very small rounds. That is not the pattern of a company that has closed its funding question. It is the pattern of a company that keeps collecting capital in small tranches while adding dilution layers along the way.
The Bottom Line
The cost of capital at Bio Meat Foodtech in 2025 was higher than the headline suggested. 40 agorot was only the outer layer. Beneath it sat the fixed 8% future units, a ratchet derivative that had already reached NIS 566 thousand within roughly two months, NIS 175 thousand of issuance costs, a warrant-life extension, and deferred internal management fees designed not to press too hard on the cash balance immediately.
So the right 2026 question is not whether the partnership managed to raise money. It did. The real question is at what price, and for how long that price bought it breathing room. As of year-end 2025 and the months right after, the answer is that Bio Meat bought expensive, complex and dilutive capital, and above all bought itself only a few more months of air.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.